|
|
Vaccine Detail
|
BC-819 |
| Vaccine Information |
- Vaccine Name: BC-819
- Target Pathogen: Cancer
- Target Disease: Cancer
- Type: DNA vaccine
- Status: Clinical trial
- Host Species for Licensed Use: None
- Immunization Route: intratumoral
- Description: BC-819 (also known as DTA-H19) is a double-stranded DNA plasmid, 4,560 base pairs (bp) in length, carrying the gene for the Diphtheria toxin A (DT-A) chain under the regulation of the H19 promoter. The DT-A chain expression is triggered by the presence of H19 transcription factors that are only up-regulated in tumor cells. The selective initiation of toxin expression results in selective tumor cell destruction via inhibition of protein synthesis selectively in the tumor cell, enabling highly targeted cancer treatment. It is used in combination with intravenously administered gemcitabine for patients with Locally Advanced Pancreatic Adenocarcinoma. (NCT01413087)
|
| Host Response |
|
|
| References |
NCT01413087: Efficacy and Safety of BC-819 and Gemcitabine in Patients With Locally Advanced Pancreatic Adenocarcinoma (LAPC-BC-819) [https://clinicaltrials.gov/study/NCT01413087]
|
|
